Beta blockers are the most effective therapy for heart failure according to clinical trials. Long term use of beta blockers such as bisoprolol, carvedilol, and sustained release metoprolol succinate can reduce mortality, heart failure hospitalizations, and improve ejection fraction and symptoms of heart failure. While initiation requires slow uptitration, discontinuation of beta blockers during heart failure hospitalization is generally not necessary and may worsen outcomes.
Hypertension remains difficult to treat effectively despite available drugs. Aggressive treatment of moderate and mild hypertension through combinations of drugs from different classes leads to better outcomes. Combination therapy is recommended to control blood pressure as it is more effective than monotherapy due to targeting multiple mechanisms. Fixed-dose combinations have advantages over individual drugs such as better blood pressure control, fewer side effects, and increased compliance.
The document discusses drugs used to treat heart failure. It begins with an overview of heart failure and its pathophysiology. It then describes several classes of drugs used to treat heart failure, including:
1. Diuretics such as furosemide to reduce fluid overload and relieve symptoms.
2. Renin-angiotensin system inhibitors like ACE inhibitors and ARBs to prevent pathological remodeling and progression of heart failure.
3. Beta-blockers like carvedilol and metoprolol which reduce sympathetic overactivity and remodeling.
4. Other drug classes discussed include digitalis glycosides, vasodilators, aldosterone antagonists, and inotropic drugs.
Modern principles of hypertension treatmentNishuVerma20
Introduction
Classification of BP
Total Cardiovascular Risk Stratification
Pre Hypertension stage
Four main classes of medication
Medication based on the comorbidity
Combination Therapy
Treatment of acute complications
Conclusion
This document discusses drug therapy considerations in the elderly population. Key points include:
- Physiological changes that occur with aging impact drug absorption, distribution, metabolism and excretion requiring dosage adjustments.
- Polypharmacy is common due to multiple diseases and increases risk of drug interactions.
- Adverse drug reactions are more frequent in the elderly. Drugs should be started at low doses and titrated carefully.
- Drug selection should consider potential side effects, dosage forms that are easy to take, and affordability. Close monitoring for side effects is important.
The document discusses heart failure, including its definition, causes, pathophysiology, clinical features, investigations, therapeutic objectives, and treatment options. Heart failure results from impaired ventricular filling or ejection and causes symptoms like dyspnea and fatigue. It can be caused by systolic or diastolic dysfunction from various structural heart diseases. Treatment aims to improve symptoms and prolong survival through lifestyle changes, medications like diuretics, ACE inhibitors, beta-blockers, and devices or procedures for advanced cases. Digoxin is also used to improve symptoms in some heart failure patients.
mono-therapy vs. combination therapy in hypertensionAhmed Taha
Initial combination therapy is superior to sequential mono-therapy for treating hypertension. Combination therapy controls blood pressure faster by acting on multiple mechanisms, reducing complications by 40-54%. Combinations have greater efficacy, improve adherence, and have protective effects beyond blood pressure lowering like anti-inflammatory and metabolic benefits. Clinical trials show combination therapy achieves better blood pressure control rates and lowers cardiovascular events compared to mono-therapy. Therefore, guidelines recommend starting treatment for hypertension with initial combination therapy.
1. The document discusses guidelines and strategies for the prevention, treatment, and control of hypertension.
2. It outlines 4 stages of intervention for hypertension: preventive, primary, secondary, and resistant hypertension. Treatment approaches differ depending on the stage.
3. The challenges of controlling hypertension include special patient populations, factors influencing drug choice, and issues related to resistant hypertension when blood pressure remains high despite treatment with 3 drug classes.
Anti-hypertensive agent and Recent developementsnamanjain727
1.To study chemistry, SAR, mechanism of action, side effects, therapeutic uses of various anti-hypertensive drugs.
2.To emphasize on the newer current upcoming drugs for the treatment of hypertension.
Amiodarone is a complex antiarrhythmic drug used for treating life-threatening ventricular arrhythmias and atrial fibrillation. It has a long half-life of 58 days and can cause various adverse effects if used long-term at higher doses, including pulmonary toxicity, thyroid abnormalities, skin discoloration, and interactions with other drugs. Patients on amiodarone require regular monitoring for efficacy and side effects, especially monitoring of thyroid function every 3-6 months due to risks of hypothyroidism and hyperthyroidism.
Dobutamine is a synthetic catecholamine and beta-1 agonist used as a vasopressor and inotropic agent. It works by directly stimulating beta-adrenergic receptors in the heart muscle to increase contractility and cardiac output. Dobutamine has a rapid onset of action of 2 minutes when administered intravenously and a short plasma half-life of 2 minutes. It is indicated for use in cardiac failure, open heart surgery, and as an alternative to exercise in cardiac stress testing to evaluate heart function. Common adverse effects include increased heart rate, blood pressure changes, and chest pain. Dobutamine must be administered cautiously in patients with recent heart attacks or ischemia.
The document discusses adverse drug reactions (ADRs). It defines ADRs and different types including: Type A reactions which are augmented/predictable effects; Type B which are bizarre/unpredictable; Type C seen with continuous use; Type D which are delayed effects; Type E occurring at the end of a dose; and Type F resulting from treatment failure. It provides examples and management strategies for each type of ADR.
This document discusses the drug Amiodarone, used to treat arrhythmias. It begins by providing the systematic name and categories of risk for cardiovascular drugs during pregnancy. It then discusses Amiodarone's history, mechanisms of action, indications, contraindications, interactions, excretion, dosing, and various side effects affecting lungs, thyroid, eyes, skin, liver and other organs. References are provided at the end.
Metoprolol is a beta-blocker used to treat hypertension, angina, and myocardial infarction. It works by blocking beta-1 receptors in the heart, lowering heart rate and blood pressure. Common side effects include dizziness, fatigue, shortness of breath, and diarrhea. It interacts with many other drugs and its effects are influenced by CYP2D6 metabolism and genetic polymorphisms. To improve safety, medication reconciliation should be done within 20 minutes of admission and the profile updated regularly while educating the patient.
This document provides basic drug information about Sintrom, which contains the active ingredient acenocoumarol. It is used to treat and prevent thromboembolic diseases. The tablets come in a 4 mg dose. It works by inhibiting the production of vitamin K-dependent clotting factors in the liver. Its effects can be seen within 36-72 hours and it has a narrow therapeutic index, so regular coagulation monitoring and dose adjustments are required for safe use. Common side effects include bleeding, while an overdose can cause serious or fatal hemorrhage.
This document discusses the indications and use of beta blockers in pediatrics. It covers their role in heart failure, cyanotic heart disease, hypertension, infantile hemangiomas, migraine, and portal hypertension. For heart failure, carvedilol is the most studied beta blocker and dosing begins at 0.1 mg/kg/day. For cyanotic spells, IV propranolol or esmolol can be given. Propranolol is also effective for infantile hemangiomas when started at 1 mg/kg/day and increased to 2-3 mg/kg/day. Beta blockers are also used for migraine prophylaxis and to decrease portal blood flow in portal hypertension.
This document discusses drugs used to treat cardiovascular diseases, focusing on digoxin. It notes that digoxin is widely prescribed for congestive heart failure and its levels are therapeutically monitored. Immunoassays are commonly used to measure digoxin levels but can be affected by other compounds. The document outlines indications, signs of toxicity, therapeutic ranges, and monitoring requirements for digoxin therapy. It discusses factors that can increase toxicity risk like medications and conditions that alter tissue sensitivity. The importance of therapeutic drug monitoring for digoxin is also covered.
Statins are a class of drugs that lower cholesterol by inhibiting its production in the liver. They have been shown to significantly reduce risks of cardiovascular events. While generally safe and effective for primary prevention when LDL is over 190 mg/dL, statins can cause side effects like muscle pain and cognitive issues. They work best when started before or after CABG to improve graft patency. Rosuvastatin and atorvastatin may provide the greatest benefits for postoperative CABG patients by allowing LDL to be lowered below 100 mg/dL. Maintaining LDL at this level can nearly double venous graft patency rates.
This document discusses how various drugs can interfere with thyroid function. It begins by defining primary and central hypothyroidism. It then explains how drugs can disrupt thyroid hormone synthesis, alter thyroid autoimmunity, and affect follicular cell activity. Specific drugs like amiodarone, lithium, and cytokines are highlighted. The document also discusses how drugs can interfere with T4 metabolism and conversion to T3. It provides examples of medications that can alter thyroid function tests or T4 binding. Finally, it emphasizes the importance of recognizing drug interactions to correctly interpret thyroid tests and treat patients.
This document discusses hypertension and classifications of blood pressure. It then summarizes various categories of antihypertensive agents including their mechanisms of action, examples of medications, therapeutic uses, and side effects. Nursing implications are provided around monitoring blood pressure during therapy, ensuring proper administration of medications, and lifestyle education to support treatment.
The document discusses several topics:
1. Baxdrostat, a new drug to treat resistant hypertension by inhibiting aldosterone synthase. It was well tolerated in trials and significantly lowered blood pressure.
2. Finerenone, a mineralocorticoid receptor antagonist approved to reduce kidney disease progression in type 2 diabetes. It has fewer side effects like hyperkalemia than existing drugs.
3. Zavegepant, the first intranasal CGRP receptor antagonist approved for acute migraine treatment. It provided pain relief within 2 hours and was generally well tolerated in trials.
4. New guidelines for gastroparesis diagnosis and management, recommending pharmacologic treatment like metoclopramide
The document discusses antihypertensive agents, providing an overview and classification of types including diuretics, beta blockers, calcium channel blockers, and their mechanisms of action. It covers the indications, dosages, side effects, and toxicity management of these classes of antihypertensive drugs used to treat hypertension.
This document discusses the toxicities of targeted cancer therapies. It begins by defining targeted therapy and describing the ideal features of an anticancer target. It then outlines several common toxicities of targeted therapies including cardiovascular issues like hypertension and ventricular dysfunction, QTc prolongation, thromboembolic complications, and various skin toxicities. Specific mechanisms, risk factors, management strategies, and monitoring approaches are described for each toxicity.
This document discusses the principles of drug therapy for hypertension. It defines hypertension and outlines the risks of not treating it. The main types of hypertension are essential and secondary hypertension. Lifestyle factors like stress, sodium intake, obesity, and smoking can increase risk. The JNC 7 and 8 guidelines classify and recommend treatment for various blood pressure levels. The renal, baroreceptor, and renin-angiotensin systems help regulate blood pressure. Most antihypertensive drugs act by interfering with these normal mechanisms. Initial treatment typically involves a single drug, with combination therapy used if targets are not met. Drug selection depends on individual patient factors and comorbidities.
The document discusses challenges in pharmacotherapy for geriatric patients. It notes that illness is more common in older adults, leading to high rates of polypharmacy. Age-related changes can impact absorption, distribution, metabolism and excretion of drugs. This generally results in lower clearance and increased sensitivity to medications. Drug-drug and drug-disease interactions are also more common. The document provides prescribing pearls like starting low doses and avoiding high risk medications. It emphasizes the need for careful monitoring to optimize outcomes for geriatric patients.
This document discusses stroke pathophysiology, risk factors, treatment goals, and pharmacotherapy options. It begins by outlining the objectives of the lecture. It then defines stroke types, provides mortality rates, and reviews modifiable and nonmodifiable risk factors. Treatment goals are identified as reducing injury, preventing complications, and recurrence. Pharmacotherapy options discussed for acute ischemic stroke include thrombolytics such as alteplase, streptokinase, reteplase and tenecteplase. Dosing, mechanisms of action, and adverse effects are reviewed for each thrombolytic.
This document discusses key concepts in clinical pharmacology and therapeutics as they relate to a case study of a 67-year-old patient. It covers drug-drug, drug-disease, and drug-patient interactions to consider for the patient's medications. It proposes a therapeutic regimen for the patient and monitoring criteria. It also reviews principles of pharmacodynamics, how drugs act in the body, and pharmacokinetics, what the body does to drugs, including absorption, distribution, metabolism and excretion.
This document discusses key issues in geriatric pharmacotherapy. It covers how aging affects drug absorption, distribution, metabolism and elimination in the body. It also discusses challenges like polypharmacy and increased risk of adverse drug events. The principles of optimal prescribing for older patients focus on starting with lower doses, avoiding unnecessary medications, and carefully monitoring for drug interactions and side effects.
This document summarizes drug-induced cardiovascular diseases. It discusses how drugs can cause cardiac arrhythmias, heart failure, changes in blood pressure, and other issues. Digitalis, quinidine, antiarrhythmics, antidepressants, and sympathomimetics are some of the drugs that can induce arrhythmias. Beta-blockers may precipitate heart failure in vulnerable patients. Alcohol, anthracyclines, and catecholamines can cause cardiomyopathy. Contraceptive steroids increase the risk of hypertension, myocardial ischemia, and venous thrombosis. Corticosteroids, licorice, and nonsteroidal anti-inflammatories may also raise blood pressure.
This document provides information about the Nebraska Geriatrics Workforce Enhancement Program (NGWEP). It is a partnership between Nebraska Medicine, UNMC, community organizations, and primary care sites supported by funding from HRSA. The program focuses on age-friendly primary care and improving care for older adults, with a focus on optimizing medication use (the 4Ms) in older patients. The document includes objectives about understanding changes in aging physiology that impact drug use in seniors and identifying risks of polypharmacy and inappropriate prescribing. It also provides guidance on prescribing principles for older adults.
Nifedipine is the active ingredient in PROCARDIA XL, which is an extended release tablet used to treat hypertension and chest pain called angina. It works by blocking calcium channels and relaxing blood vessels. PROCARDIA XL tablets have an osmotic pump system that slowly releases nifedipine over 24 hours for continuous effect. Common side effects include headache, dizziness, and ankle swelling. It can be used alone or combined with other blood pressure medications and is generally started at a low dose that is increased gradually based on the patient's response.
This document discusses the pharmacotherapy of hypertension. It defines hypertension and classifies blood pressure readings. The main types of drugs used to treat hypertension work by decreasing cardiac output and/or total peripheral resistance. These include diuretics, sympathoplegic agents like methyldopa and beta blockers, vasodilators, ACE inhibitors, and calcium channel blockers. The document provides details on the mechanisms and uses of these drug classes and recommends treatment approaches based on hypertension severity.
1. The document discusses how stress and anxiety can trigger a "fight or flight" response leading to increased blood pressure and heart rate in patients prior to dental surgery.
2. It provides guidelines for evaluating hypertensive patients before dental treatment, including assessing cardiovascular risk factors, functional capacity, and blood pressure levels to determine safety.
3. For hypertensive patients requiring emergency dental treatment, it recommends precautions like using local anesthetics without vasoconstrictors or employing hypotensive anesthesia to control blood pressure and minimize risks of complications like heart attack or stroke.
Hypertension, or high blood pressure, is classified as either primary (essential) or secondary. Primary hypertension accounts for 90% of cases and has no identifiable cause, while secondary hypertension is caused by an underlying condition like renal disease. Treatment involves lifestyle modifications and medication, with thiazide diuretics often used as initial therapy. Other common drug classes for treatment include ACE inhibitors, calcium channel blockers, beta blockers, and alpha blockers. Multiple drug therapy is usually required to control hypertension.
Digoxin toxicity is caused by digoxin, a plant-derived cardiac glycoside used to treat heart conditions. It has a narrow therapeutic window, so toxicity can easily occur. Common signs of toxicity include arrhythmias such as heart block or tachycardia. Management involves discontinuing digoxin, treating arrhythmias, correcting electrolyte imbalances, and using digoxin antibody fragments for severe toxicity. Factors like renal impairment, hypokalemia, and drug interactions can precipitate or worsen digoxin toxicity.
Need for Therapeutic Drug Monitoring, Factors to be considered during the Therapeutic Drug Monitoring, and Indian scenario for Therapeutic Drug Monitoring.
This document provides information about cardiovascular drugs. It begins by defining blood pressure and hypertension. It then discusses various classes of antihypertensive drugs, including beta blockers like propranolol and metoprolol, ACE inhibitors, calcium channel blockers, and diuretics. Beta blockers work by decreasing cardiac output and peripheral resistance to lower blood pressure. Propranolol is a nonselective beta blocker while metoprolol is a selective beta1 receptor blocker, making it safer for patients with asthma or COPD. The document provides details on the mechanisms and effects of various antihypertensive agents.
Similar to Drugs pharmacology in heart disease (20)
This document discusses various statistical concepts including outliers, transforming data, normalizing data, weighting data, robustness, and homoscedasticity and heteroscedasticity. Outliers are values far from other data points and should be carefully examined before removing. Data can be transformed using logarithms, square roots, or other functions to better fit a normal distribution or equalize variances between groups. Normalizing data puts variables on comparable scales. Weighting data adjusts for under- or over-representation in samples. Robust tests are resistant to violations of assumptions. Homoscedasticity refers to equal variances between groups while heteroscedasticity refers to unequal variances.
The document provides an overview of correlation, regression, and other statistical methods. It defines correlation as measuring the association between two variables, while regression finds the best fitting line to predict a dependent variable from an independent variable. Simple linear regression uses one predictor variable, while multiple linear regression uses two or more. Logistic regression is used for nominal dependent variables. Nonlinear regression fits curved lines to nonlinear data. The document provides examples and guidelines for choosing the appropriate statistical test based on the type of variables.
This document provides an overview of various statistical tests for comparing variables, including t-tests, ANOVA, MANOVA, ANCOVA, and MANCOVA. It defines each test and provides examples of their proper usage. T-tests are used to compare two groups on a continuous variable, including paired and unpaired, parametric and non-parametric versions. ANOVA and MANOVA are used to compare three or more groups and two or more dependent variables, respectively. ANCOVA and MANCOVA control for covariates/confounding variables in one-way and two-way designs with single or multiple dependent variables. Examples and best practices are given for selecting and conducting each type of test.
This document discusses key concepts in applied statistics including hypothesis testing, p-values, types of errors, sensitivity and specificity. It provides examples and explanations of these topics using scenarios about testing if feeding chickens chocolate changes the gender ratio of offspring. Hypothesis testing involves defining the null and alternative hypotheses and using a statistical test to either reject or fail to reject the null hypothesis based on the p-value. Type I and type II errors in hypothesis testing are explained. Sensitivity and specificity in diagnostic tests are introduced using an example about detecting if a car is being stolen.
This document provides an introduction to applied statistics and various statistical concepts. It discusses the normal (Gaussian) distribution, standard deviation, standard error of the mean, and confidence intervals. Examples and explanations are provided for each concept. Hands-on examples for calculating these statistics in Excel, SPSS, and Prism are also presented. The document aims to explain key statistical terms and how they are applied in data analysis.
a clinically oriented discussion of blood coagulation and related diseases and treatment. also discussing DIC, plasma fractions and anti-platelet drugs.
HMG-CoA reductase inhibitors, commonly known as statins, are the primary drugs used to treat dyslipidemia. They work by inhibiting cholesterol production in the liver, leading to increased clearance of LDL cholesterol from the bloodstream. Fibrates also effectively lower triglyceride levels by increasing fatty acid metabolism. Bile acid sequestrants function by binding bile acids in the gut, enhancing their excretion and increasing LDL receptor activity in the liver. Combination drug therapies that target multiple lipid abnormalities can provide improved treatment outcomes over single agents alone.
This document discusses various immunopharmacology drugs and their uses. It covers immunosuppressive antibodies including monoclonal antibodies used for transplantation, cancer, and autoimmune diseases. It also discusses immunosuppressive drugs classified as immunophilin ligands or cytotoxic agents that are used for transplantation and graft-versus-host disease. Common drugs discussed include cyclosporine, tacrolimus, sirolimus, mycophenolate, azathioprine, and cyclophosphamide.
The document provides guidance on rational prescription writing, including introducing the concept of "P-drugs" or personal first-choice drugs, outlining the steps in prescription writing, common abbreviations, and important instructions and information to provide to patients. It also discusses medication errors and how electronic prescribing can help reduce errors by suggesting alternative drugs. The overall goal is to teach students how to properly treat patients through skillful prescribing rather than just knowledge of drugs.
This document discusses the use of various drugs during pregnancy and lactation. It covers analgesics, antihypertensives, chemotherapeutics, central nervous system drugs, anticoagulants, endocrine drugs, antiemetics, antihistamines, and others. For each drug class or individual drug, it notes any potential risks to the fetus, such as teratogenicity, and recommendations for use during pregnancy and effects on the newborn. The overall message is that many drugs should be avoided during pregnancy if possible due to risks of harming fetal development, and careful consideration of risks and benefits is needed for drug treatment during this period.
This document discusses drug use during pregnancy and lactation. It covers principles of therapy during pregnancy and lactation, emphasizing using the lowest effective dose for shortest time. Physiologic and pharmacokinetic changes in pregnancy that affect drug distribution and metabolism are described. The fetal circulation is explained, as well as how drugs can affect the fetus. Drug categories in pregnancy from A to X are defined based on safety evidence. Common issues in pregnancy like anemia, constipation, and gestational diabetes are also covered.
This document discusses drug use during pregnancy and lactation. It covers the effects of non-therapeutic drugs like alcohol, caffeine, cigarettes, cocaine and marijuana on the fetus. It also discusses the management of selected medical conditions in pregnancy like AIDS, UTI, asthma, diabetes, hypertension and epilepsy. The final sections discuss neonatal therapeutics including vitamin K administration and treatment of ophthalmia neonatorum. It concludes with guidance on drug use during lactation, identifying drugs that are generally safe and those that require caution.
This document discusses methemoglobinemia, which is a condition caused by elevated levels of methemoglobin in the blood. Methemoglobin cannot carry oxygen, so symptoms range from cyanosis to death depending on levels. It may be congenital or acquired through medications, chemicals, and certain foods. Diagnosis involves blood tests showing abnormal hemoglobin color. Treatment focuses on reducing methemoglobin back to hemoglobin, primarily using methylene blue or ascorbic acid. The document also briefly covers cyanide poisoning, which causes tissue anoxia and can be fatal within minutes of inhalation.
This document provides guidance on proper academic writing style and conventions. It discusses things to avoid such as adjectives, negatives, long sentences, and colloquial language. It also covers proper use of punctuation like commas, semicolons, and apostrophes. Connectors are addressed to link ideas clearly. The document aims to improve clarity, precision and formality of academic writing.
This document provides an overview of the key elements of academic writing, including:
- How to structure an academic paper, with sections like the title, abstract, introduction, methods, results, discussion, and conclusion.
- Guidelines for writing each section, such as keeping the introduction brief, describing the methods in detail, and highlighting the main findings in the results.
- Tips for writing style, including using a cautious style, generalizations supported by evidence, and avoiding absolute statements.
More from Mohammad Hadi Farjoo MD, PhD, Shahid behehsti University of Medical Sciences (20)
Causes Of Tooth Loss
PERIODONTAL PROBLEMS ( PERIODONTITIS, GINIGIVITIS)
Systemic Causes Of Tooth Loss
1. Diabetes Mellitus
2. Female Sexual Hormones Condition
3. Hyperpituitarism
4. Hyperthyroidism
5. Primary Hyperparathyroidism
6. Osteoporosis
7. Hypophosphatasia
8. Hypophosphatemia
Causes Of Tooth Loss
CARIES/ TOOTH DECAY
Causes Of Tooth Loss
CAUSES OF TOOTH LOSS
Consequence of tooth loss
Anatomic
Loss of ridge volume both height and width
Bone loss :
mandible > maxilla
Posteriorly > anteriorly
Anatomic consequences
Broader mandibular arch with constricting maxilary arch
Attached gingiva is replaced with less keratinised oral mucosa which is more readily traumatized.
Anatomic consequences
Tipping of the adjacent teeth
Supraeruption of the teeth
Traumatic occlusion
Premature occlusal contact
Anatomic Consequences
Anatomic Consequences
Physiologic consequences
Physiologic Consequences
Decreased lip support
Decreased lower facial height
Physiologic Consequences
Physiologic consequences
Education of Patient
Diagnosis, Treatment Planning, Design, Treatment, Sequencing, and Mouth Preparation
Support for Distal Extension Denture Bases
Establishment and Verification of Occlusal Relations and Tooth Arrangements
Initial Placement Procedures
Periodic Recall
Education of Patient
Informing a patient about a health matter to
secure informed consent.
Patient education should begin at the initial
contact with the patient and should continue throughout treatment.
The dentist and the patient share responsibility for the ultimate success of a removable partial denture.
This educational procedure is especially important when the treatment plan and prognosis are discussed with the patient.
Diagnosis, Treatment Planning, Design, Treatment, Sequencing, and Mouth Preparation
Begin with thorough medical and dental histories.
The complete oral examination must include both clinical and radiographic interpretation of:
caries
the condition of existing restorations
periodontal conditions
responses of teeth (especially abutment teeth) and residual ridges to previous stress
The vitality of remaining teeth
Continued…..
Occlusal plan evaluation
Arch form
Evaluation of Occlusal relationship through mounting the diagnostic cast
The dental cast surveyor is an absolute necessity in which patients are being treated with removable partial dentures.
Mouth preparations, in the appropriate sequence, should be oriented toward the goal of
providing adequate support, stability,
retention, and
a harmonious occlusion for the partial denture.
Support for Distal Extension Denture Bases
A base made to fit the anatomic ridge form does not provide adequate support under occlusal loading.
The base may be made to fit the form of the ridge when under function.
Support for Distal Extension Denture Bases
This provides support
Hemodialysis: Chapter 8, Complications During Hemodialysis, Part 2 - Dr.GawadNephroTube - Dr.Gawad
- Video recording of this lecture in English language: https://youtu.be/FHV_jNJUt3Y
- Video recording of this lecture in Arabic language: https://youtu.be/D5kYfTMFA8E
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Join the leading All Range PCD Pharma Franchise in India and grow your business with a trusted partner. We offer an extensive range of high-quality pharmaceutical products, competitive pricing, and comprehensive marketing support. Benefit from our expertise, wide distribution network, and excellent customer service. Elevate your pharma business with See Ever Healthcare's proven PCD franchise model.
https://www.seeeverhealthcare.com/all-range-pcd-pharma-franchise-in-india/
Chair and Presenter, Stephen V. Liu, MD, Benjamin Levy, MD, Jessica J. Lin, MD, and Prof. Solange Peters, MD, PhD, discuss NSCLC in this CME/MOC/NCPD/AAPA/IPCE activity titled “Decoding Biomarker Testing and Targeted Therapy in NSCLC: The Complete Guide for 2024.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/4bBb8fi. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 1, 2025.
Chemical kinetics is the study of the rates at which chemical reactions occur and the factors that influence these rates.
Importance in Pharmaceuticals: Understanding chemical kinetics is essential for predicting the shelf life of drugs, optimizing storage conditions, and ensuring consistent drug performance.
Rate of Reaction: The speed at which reactants are converted to products.
Factors Influencing Reaction Rates:
Concentration of Reactants: Higher concentrations generally increase the rate of reaction.
Temperature: Increasing temperature typically increases reaction rates.
Catalysts: Substances that increase the reaction rate without being consumed in the process.
Physical State of Reactants: The surface area and physical state (solid, liquid, gas) of reactants can affect the reaction rate.
Why Does Seminal Vesiculitis Causes Jelly-like Sperm.pptxAmandaChou9
Seminal vesiculitis can cause jelly-like sperm. Fortunately, herbal medicine Diuretic and Anti-inflammatory Pill can eliminate symptoms and cure the disease.
Hepatocarcinoma today between guidelines and medical therapy. The role of sur...Gian Luca Grazi
Today more than ever, hepatocellular carcinoma therapy is experiencing profound and substantial changes.
The association atezolizumab (ATEZO) plus bevacizumab (BEVA) has demonstrated its effectiveness in the post-operative treatment of patients, improving the results that can be achieved with liver resections. This after the failure of the use of sorafenib in the already historic STORM study.
On the other hand, the prognostic classification of BCLC is now widely questioned. It is now well recognized that the indications for surgery for patients with hepatocellular carcinoma are certainly narrow in BCLC and no longer reflect what is common everyday clinical practice.
Today, the concept of multiparametric therapeutic hierarchy, which makes the management of patients with hepatocellular carcinoma much more flexible and allows the best therapy for the individual patient to be identified based on their clinical characteristics, is gaining more and more importance.
The presentation traces these profound changes that are taking place in recent years and offers a modern vision of the management of patients with hepatocellular carcinoma.
EXPERIMENTAL STUDY DESIGN- RANDOMIZED CONTROLLED TRIALRishank Shahi
Randomized controlled clinical trial is a prospective experimental study.
It essentially involves comparing the outcomes in two groups of patients treated with a test treatment and a control treatment, both groups are followed over the same period of time. Prepare a plan of study or protocol
a. Define clear objectives
b. State the inclusion and exclusion criteria of case
c. Determine the sample size, place and period of study
d. Design of trial (single blind, double blind and triple blind method)
2. Define study population: Most often the patients are chosen from hospital or from the community. For example, for a study for comparison of home and sanatorium treatment, open cases of tuberculosis may be chosen.
3. Selection of participants by defined criteria as per plan:
Selection of participants should be done with precision and should be precisely stated in writing so that it can be replicated by others. For example, out of open cases of tuberculosis those who fulfill criteria for inclusion may be selected (age groups, severity of disease and treatment taken or not, etc.)
Randomization ensures that participants have an equal chance to be assigned to one of two or more groups:
One group gets the most widely accepted treatment (standard treatment/ gold standard)
The other gets the new treatment being tested, which researchers hope and have reason to believe will be better than the standard treatment
Subject variation: First, there may be bias on the part of the participants, who may subjectively feel better or report improvement if they knew they were receiving a new form of treatment.
Observer bias: The investigator measuring the outcome of a therapeutic trial may be influenced if he knows beforehand the particular procedure or therapy to which the patient has been subjected.
Evaluation bias: There may be bias in evaluation - that is, the investigator(Analyzer) may subconsciously give a favorable report of the outcome of the trial.
Co-intervention:
participants use other therapy or change behavior
Study staff, medical providers, family or friends treat participants differently.
Biased outcome ascertainment:
participants may report symptoms or outcomes differently or physicians
Investigators may elicit symptoms or outcomes differently
A technique used to prevent selection bias by concealing the allocation sequence from those assigning participants to intervention groups, until the moment of assignment.
Allocation concealment prevents researchers from influencing which participants are assigned to a given intervention group.
All clinical trials must be approved by Institutional Ethics Committee before initiation
It is mandatory to register clinical trials with Clinical Trials Registry of India
Informed consent from all study participants is mandatory.
A preclinical trial is a stage of research that begins before clinical trials, and during which important feasibility and drug safety data are collected.
Following points high.
Case presentation of a 14-year-old female presenting as unilateral breast enlargement and found to have a giant breast lipoma. The tumour was successfully excised with the result that the presumed unilateral breast enlargement reverting back to normal. A review of management including a photo of the removed Giant Lipoma is presented.
TEST BANK For Katzung's Basic and Clinical Pharmacology, 16th Edition By {Tod...rightmanforbloodline
TEST BANK For Katzung's Basic and Clinical Pharmacology, 16th Edition By {Todd W. Vanderah, 2024,} Verified Chapter
TEST BANK For Katzung's Basic and Clinical Pharmacology, 16th Edition By {Todd W. Vanderah, 2024,} Verified Chapter
TEST BANK For Katzung's Basic and Clinical Pharmacology, 16th Edition By {Todd W. Vanderah, 2024,} Verified Chapter
High Profile"*Call "*Girls in Kolkata ))86-075-754-83(( "*Call "*Girls in Kol...Nisha Malik Chaudhary
High Profile "*Call "*Girls in Kolkata ))86-075-754-83(( "*Call "*Girls in Kolkata Available
Kolkata "Call "Girls 74046-34175 "Call "Girl Number in Kolkata | A nutshell review for Hot "Call "Girls in Kolkata . MY experience was superb with them this is the only recommended "Call "Girls service in Kolkata "Call "Girls and again then Russian. so overall my practice was magnificent. The price is also moderate per hour. The plus point is the "Girl comes instantly to your lo"Cation doesn't matter you are in Bur Kolkata or al Nahda or Kolkata or any area she comes undeviatingly to your hotel room. Definitely recommend the "Call "Girls agency. A nutshell review for Hot "Call "Girls in Kolkata . MY experience was superb with them this is the only recommended "Call "Girls service in Kolkata with verified "Call "Girls . I am using their services from past 6 months they never ever disappointed me in any way. Let's just say if i asked them to provide me russian "Call "Girls they fulfilled my request or even beautiful "Call "Girls or indian "Call "Girls in Kolkata . They have their owen drivers who brings the "Call "Girls in less time in any area of Kolkata like bur Kolkata marina or jumeirah or even in jebel ali as well. I'm writing here everything after experience their services in all conditions.
Pharmacotherapy of Asthma and Chronic Obstructive Pulmonary Disease (COPD)HRITHIK DEY
This PowerPoint presentation provides an in-depth overview of the pharmacotherapy approaches for managing asthma and Chronic Obstructive Pulmonary Disease (COPD). It covers the pathophysiology of these respiratory conditions, the various classes of medications used, their mechanisms of action, indications, side effects, and the latest treatment guidelines. Designed for students, healthcare professionals, and anyone interested in respiratory pharmacology, this presentation offers a comprehensive understanding of current therapeutic strategies and advancements in the field.
Exploring Alternatives- Why Laparoscopy Isn't Always Best for Hydrosalpinx.pptxFFragrant
Not all women with hydrosalpinx should choose laparoscopy. Natural medicine Fuyan Pill can also be a nice option for patients, especially when they have fertility needs.
Exploring Alternatives- Why Laparoscopy Isn't Always Best for Hydrosalpinx.pptx
Drugs pharmacology in heart disease
2. Drugs Pharmacology in Heart Disease
By
M.H.Farjoo M.D. , Ph.D.
Shahid Beheshti University of Medical Sciences
3. Drugs Pharmacology in Heart Disease
Principles of Drug Therapy
Variability in Drug Effect
Dosage Optimization
Drug Therapy in the Elderly
Polypharmacy
4. Principles of Drug Therapy
The fundamental assumption for any drug is that the
benefit exceeds the risk.
The goals of drug therapy in heart disease include:
Acute correction of serious pathophysiology
Symptom relief
Changes in “surrogate” endpoints (blood pressure,
serum cholesterol, INR)
5. Principles of Drug Therapy
A survey (CAST) tested the hypothesis that
suppression of ventricular ectopic beats would reduce
mortality.
CAST proved that some antiarrhythmics suppressed
ventricular ectopic beats but increased mortality
threefold.
In heart failure positive inotropic drugs are used but
increase mortality (drug-induced arrhythmias).
Prescribers should be cautious about therapy in the
absence of controlled clinical trials.
6. Principles of Drug Therapy
The risks of drug therapy may be:
Related to its pharmacological actions:
Excessive hypotension due to antihypertensives
Bleeding due to anti platelet drugs
Unrelated to its action:
Rhabdomyolysis with statins (eg: atorvastatin)
Angioedema due to ACEI therapy
Torsades de pointes by thioridazine or pentamidine.
7. Variability in Drug Effect
Variability in drug effect is due to:
Pharmacokinetic parameters
Pharmacodynamic parameters
Pharmacogenomics parameters
8. Pharmacokinetic Parameters
Cardiovascular disorders that impair cardiac output
may affect all the pharmacokinetic factors:
Absorption of oral, SC, IM, and topical drugs is
erratic because of decreased blood flow to sites of
drug administration.
Distribution is impaired because of decreased
blood flow to sites of drug action.
Metabolism and excretion are impaired because of
decreased blood flow to the liver and kidneys.
9. Pharmacokinetic Parameters
Failure of one metabolizing pathway will not affect a
drug using multiple elimination routes.
A drug eliminated by one pathway will accumulate if
the pathway fails.
In this case there is a risk of toxicity, especially if
therapeutic margin is narrow.
11. Pharmacokinetic Parameters
An example is terfenadine, which is eliminated
exclusively by CYP3A.
Terfenadine is a highly potent QT-prolonging agent.
Terfenadine with CYP3A inhibitors (ketoconazole,
Erythromycin) causes QT prolongation, and torsades
de pointes.
CYP3A inhibition also increases the risk of
rhabdomyolysis with some statins and Fibrates.
13. Torsade depointes
Polymorphic V.Tach. (torsades de pointes), which may degenerate into V. Fib.
There is a high risk of sudden death in this syndrome.
14. Pharmacokinetic Parameters
Patients with LVH have baseline QT prolongation, so
risk of QT-prolonging antiarrhythmics increases.
In heart failure, hepatic congestion decreases
clearance and an increases toxicity with usual doses
of lidocaine and β blockers.
In heart failure renal perfusion is reduced and
requires dose adjustments.
Heart failure causes redistribution of regional blood
flow => volume of distribution ↓ => drug toxicity ↑
(lidocaine).
15. Pharmacokinetic Parameters
β blockers in patients with defective metabolism
produces exaggerated heart rate slowing.
Digoxin is eliminated by P-glycoprotein-mediated
efflux into bile and urine.
Inhibition of P-glycoprotein increases digoxin
concentrations.
16. Pharmacodynamic Parameters
The effect of lytic therapy in a patient with or without
coronary thrombosis is different.
The arrhythmogenic effects of digitalis depend on K+.
The vasodilating effects of nitrates, beneficial in
angina, can be catastrophic in aortic stenosis.
17. Pharmacogenomics Parameters
An example is resistance to antiplatelet actions of
aspirin and Clopidogrel (anti ADP receptor).
DNA variants are recognized as contributors to
variability in drug action.
There is associations between disease severity and
DNA polymorphisms.
This affects β blockers, ACEI, Fluvastatin, Diuretics,
Antiplatelet drugs and Amiloride.
18. effect of a beta-receptor polymorphism on receptor
function in vitro. Patients with the hypofunctional
variant may display greater heart-rate slowing or
blood pressure lowering on exposure to receptor
blocking agents.
Beta blockers
19. Dosage Optimization
When the goal of drug therapy is to acutely correct a
disturbance, drug should be administered IV.
Large IV boluses has the risk of enhancing drug-
related toxicity.
Even with the most urgent of medical indications, this
approach is rarely appropriate.
An exception is adenosine, which must be injected as
a rapid bolus (1-2 Sec.) because rapid elimination
from plasma.
21. Dosage Optimization
When adverse effects are serious, the treatment
should start at low doses.
For example, the risk of torsades de pointes increases
with sotalol dosage, the starting dose should be low.
Only when stable effects are achieved, increasing
dosage may be considered.
Drug monitoring is best accomplished at the time of
anticipated peak drug concentrations.
Assessing QT prolongation by sotalol or dofetilide is
accomplished 1 to 2 hours after a dose of drug at
steady state.
23. Drug Therapy in the Elderly
Age is a major factor in determining drug doses and
sensitivity to drug effects.
Elderly persons have reduced creatinine clearance,
even with a normal creatinine level
Dosages of renally excreted drugs should be adjusted.
Elderly have increased postural hypotension.
Thus, sedatives, TCAs or anticoagulants should be
initiated only when the benefits outweigh the risk.
24. Drug Therapy in the Elderly
Weight adjustment for loading doses of digoxin,
lidocaine and heparin are standard.
Fibrinolytic drugs without adjustment increase the
risk of intracranial hemorrhage in older age.
Dosage/weight adjustments should be made
especially for drugs with low therapeutic index.
Digoxin, warfarin, diuretics, and CCBs have
“preventable” adverse effects in elderly.
25. Drug Therapy in the Elderly
“Inappropriate” drugs in the elderly include:
Amiodarone
Clonidine
Disopyramide
Medications in patients with life expectancy too short
to achieve long-term benefits merits discontinuation.
26. Polypharmacy
The most important issue is drug interactions.
Patients omit topical drugs, eye drops, supplements,
and drugs prescribed by other practitioners.
Grapefruit juice contains CYP3A and P-glycoprotein
inhibitors, and can affect drug responses.
Timolol eye drops can produce systemic β blockade
toxicity in patients with defective metabolizing
activity.
27. Adherence
Medication adherence is lower in older patients
compared with younger patients.
Hospitalization for decompensated congestive heart
failure was due to noncompliance in 42% of elderly
patients.
28. Adherence
Contributing factors for non-adherence include:
The cost of medications
Difficulty in reading small print of written directions
Hearing impairment
Impaired memory
Inadequate instructions
Complex dosing regimens
Difficulties with packaging materials
Insufficient education on medication use.
Heart disease carries with it a number of disturbances of drug elimination and sensitivity.
Systolic dysfunction with hepatic congestion is more common in the elderly.
Vascular disease and dementia are common in the elderly and can lead to increased postural hypotension.
CCB = Ca2+ channel blockers
Adverse drug events account for up to 5 percent of hospital admissions.
The risk of side effects with cardiovascular drugs is 2.4 times that of other medications in hospitalized patients.
A complete medication history should be obtained from each patient at regular intervals.